Skip to content
EN

Back to the catalog

anavex.com
rss2American English

Anavex Life Sciences

anavex.com · American English

Anavex Life Sciences (Nasdaq: AVXL) is a biopharmaceutical leader advancing targeted CNS therapies through innovative therapeutic discovery and development.

rss2 wordpress content slash wfw atom dc sy

Open the feed

https://anavex.com/feed/

Last post
Sep 24, 2026
Posts in 24 h · 7 days · 30 days
0 · 0 · 3
Our last check
Answering
Served from
United States
Site title
Anavex Life Sciences | Advancing Therapies for Alzheimer’s and Parkinson's Disease
Text score at discovery
11,981
Format
rss2
Features in the feed
content, slash, wfw, atom, dc, sy
Community
wordpress

Posts

What our queue read from this feed. Open one to read it here, or go to the site that published it.

  1. Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting
    Sep 24, 2026 · original
    NEW YORK, NY, September 24, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company’s 2026 Annual Meeting of Stockholders (“Annual Meeting”), Anavex stockholders have voted to elect all six of its director nominees – Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Mr. Gautam Patel, Dr. Adrian Senderowicz and Dr. Claus van der Velden. Dr. Jiong Ma, Independent Chair of the Board, stated, “On behalf of the new Anavex Board of Directors, I would like to thank our stockholders for their trust and support during a pivotal time for our business. Today’s outcome reflects confidence in the Board and management team’s abilit
  2. Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees
    Sep 14, 2026 · original
    ISS Recognizes There is No Case for Change Anavex Urges Stockholders to Follow ISS’ Recommendation and Vote “FOR” ALL Six Director Nominees on the WHITE Proxy Card Today NEW YORK, NY, September 14, 2026 – Anavex Life Sciences Corp. (“Anavex” or “the Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Anavex stockholders vote on the WHITE proxy card “FOR” all six of the Company’s highly qualified director nominees standing for election at the 2026 Annual Meeting of Stockholders – Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Mr. Gautam Patel, Dr. Adrian Senderowicz and Dr. Claus van der Velden. In its report issued on September 11, 2026, ISS noted t
  3. Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
    Sep 8, 2026 · original
    NEW YORK, NY, September 8, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced it will host a conference call at 4:00 PM ET on Wednesday, September 9, 2026 , during which Interim CEO Terrie Kellmeyer, Ph.D., will discuss the Company’s clinical development strategy and priorities. Anavex Investor Call Information: A link to the live webcast of the conference call will be available on Anavex’s investor relations website at anavex.com/investors . The conference call can also be accessed by dialing 1-866-777-2509 for participants in the U.S. and Canada or 1-412-317-5413 for international participants. Participants should ask to join the Anavex call. A replay of the conference call will be available
  4. Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
    Sep 2, 2026 · original
    Anavex Life Sciences is Pleased to Regain Full Compliance with Nasdaq, Continues to Execute on Clinical Development Strategy and Advance all Three Core Indications Forward NEW YORK, NY, September 2, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires Nasdaq-listed companies to file all required periodic filings with the Securities and Exchange Commission (“SEC”). On August 28, 2026, the Company filed its outstanding Form 10-Q filings for the second and third fiscal quarters of 2026 with the SEC. The Company is now in co
  5. Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
    Aug 25, 2026 · original
    Clinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer’s Disease Clinical Study Data and Rett Syndrome Formal Meeting Request to FDA, with an IND Submission for Fragile X Syndrome Planned for September NEW YORK, NY, August 25, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today reported a business update and financial results for its third fiscal quarter ended June 30, 2026. “I am delighted to report on the continued regulatory momentum we are building across our pipeline. We have submitted all data from our Alzheimer’s disease clinical trials to our newly opened Alzheimer’s IND. Th
  6. Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees
    Aug 17, 2026 · original
    Launches VoteAnavex.com to Provide Additional Information on Anavex’s Director Nominees and How to Vote at the Annual Meeting of Stockholders NEW YORK, NY, August 17, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that the Executive Committee of the Anavex Board of Directors (the “Executive Committee”) has mailed a letter to stockholders encouraging them to vote the WHITE proxy card “FOR” all six of Anavex’s highly qualified directors standing for election at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The full text of the letter being mailed to stockholders has been filed with the U.S. Security and Exchange Commission (SEC) and is available at www.Vote
  7. Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders
    Aug 11, 2026 · original
    Files Definitive Proxy Statement and Mails Letter to Stockholders Urges Stockholders to Vote “FOR” All Six Anavex Director Nominees on the WHITE Proxy Card Underscores PVG’s Lack of Clear Plan and Inexperienced Slate of Director Nominees NEW YORK, NY, August 11, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its upcoming 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) scheduled to be held on September 24, 2026. Stockholders of record as of July 31, 2026, will be entitled to vote at the meeting. Anavex’s definitive proxy materials can be accessed for fre
  8. Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
    Aug 3, 2026 · original
    Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life Sciences Mr. Patel and Dr. Senderowicz to Stand for Election at 2026 Annual Meeting with Independent Directors Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger and Dr. Claus van der Velden Urges Stockholders to Reject Attempt by PVG Asset Management Corporation and Patrick S. Adams to Acquire Control of the Company Issues Open Letter to Stockholders and Files Preliminary Proxy Statement NEW YORK, NY, August 3, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that the Executive Committee of the Company’s Board of Directors (the “Executive Committee”) has t
  9. Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
    Jul 30, 2026 · original
    Establishing Disciplined, Data-Driven Strategy with Focus on FDA Engagement for Alzheimer’s Disease NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) diseases with high unmet medical needs, today reported preliminary financial results for its fiscal second quarter ended March 31, 2026. The Company’s primary focus is on advancing its lead compound ANAVEX®2-73 (blarcamesine) in the Company’s clinical program for the treatment of mild cognitive impairment (“MCI”) due to Alzheimer’s disease (“AD”) and mild AD (collectively known as “early AD”), and for Rett syndrome and Fragile X syndrome, both of which are neurodevelopmental rare diseases. “Anavex remains firmly committed to our lead candidate oral blarcamesine (A
  10. Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
    May 22, 2026 · original
    NEW YORK, NY, May 22, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026. The Notice indicates that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”) as a result of the Company’s inability to timely file its Form 10-Q for the quarterly period ended March 31, 2026. As indicated in the Notice, the Company has until July 20, 2026, to submit a plan to regain compliance. The Company is working prudently to complete and file the Form 10-Q and submit a plan to regain compliance with the Nasdaq Listing Rule. T

Discovered by the rss-feed-index crawler, which checks each feed at most once a month.

Same record as JSON: https://api.agentalog.com/api/feeds/fd_anavex_com_291bc63643c9918c. More from this site: anavex.com in the Feeds tab.